stiller Mitleser hat endlich auch mal was zu sagen... :-)
Mon, 30 Oct 2006 18:22:25
Ich hab Herrn Bruce K. Redding eine Anfrage betr. schriftlicher Vorbehalte im Falle einer Vermarktung des, so wir doch in unserem und im Namen vor allem auch der diabetesbetrofenen Menschen hoffen wollen, lachen PRODUKTES!!
So jetzt beende ich mal den Satz und jump in die Heia . hoffe es ist interessant für euch, für mich allemal ..
cu
Sontra Medical has not brought any legal action against Dermisonics. Their news release in February was after we had just executed a confidentiality agreement with them. They did not give us an opportunity to review their claims prior to their "announcement". Here are some critical facts for you:
1) There is one U-Strip patent issued and another at notice of allowance. In each instance NONE of the Sontra patents were cited against our work, and in the United States the examiner has to acknowledge that he reviewed all the "Search Material". In that search citing all of Sontra\'s patents were reviewed but found not relevant. The Search Material included the periodicals and patents searched by the examiner and two sets of materials we sent along with the patent application, a Bibliography book and our own patent search conducted on "electronic" means of transdermal drug delivery. Our Bibliography book contained publications in the field going back to 1964 and our patents search included the work done by MIT researchers ( now Sontra Medical). None of these were cited against us.
2) Sontra originally claimed we "potentially" infringed on the ?543 patent but that patent has already expired. At the very least we have freedom to operate with regards to that patent, but again it was not cited against us.
US Patent No: 4657543
Issued : 04/14/1987
Expired: 04/14/2004
Langer Et Al.
3) The other claims in subsequent Sontra patents may be ruled INVALID in light of the Griffin Early sonophoresis research, which apparently may not have been reviewed by the patent examiner when Sontra made its applications.
1. Griffin, J.E. et al., "Ultrasonic movement of cortisol into pig tissue" Amer. J. Phys. Medicine (1965) 44(1):20-25.
2. Griffin, J.E. et al., "Physiological effects of ultrasonic energy as it is used clinically" J. Amer. Phys. Therapy Assoc. (1966) 46:18-26.
3. Griffin, J.E. et al., "Patients treated with ultrasonic driven hydrocortisone and with ultrasound alone" Phys. Therapy (1967) 47(7):594-601.
4. Griffin, J.E. et al., "Low-intensity phonophoresis of cortisol in swine" Phys. Therapy (1968) 48(12):1336-1344.
Griffin, J.E. et al., "Effect of ultrasonic frequency on phonophoresis of cortisol into swine tissues" Amer. J. Phys. Medicine (1972) 51(2):62-72
4) The U-Strip claims alternating sonic waveforms as the means of effecting pore enlargement. That was unique.
A wearable, programmable system was not covered by Sontra and others in the field.
A system which delivers a sonic transmission through the patch was not envisioned.
These and other critical claims separate our work from the Sontra research
Dermisonics has requested a freedom to operate opinion from a outside patent counsel in relation to not only Sontra, but to anyone else with IP in the electronic transdermal delivery field. When that report is in we will make that announcement and send you a copy.
In another approach we have met with Sontra and looked at their technology which is focused now in diagnostic non-invasive glucose detection. We are exploring potential joint development relationships relative to that technology base as it may assist our insulin delivery program. There can be no assurance that a relationship can be established with Sontra but we are exploring options.
If there are any questions please feel free to call.
Best Regards
Bruce K. Redding, Jr.
Encapsulation Systems Inc.
PO Box 759
Broomall, PA 19008 USA
610-543-0800 ph
610-543-0688 fax
brucer@encsys.com
aufmerksamZwinkern
|
Thread abonnieren
ETF-Sparplan